Benchmark Capital upgrades CV Therapeutics (Nasdaq: CVTX) from Hold to Buy. Price target $11.

Benchmark analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE